Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
23 10 2020
Historique:
received: 12 09 2020
revised: 16 10 2020
accepted: 21 10 2020
entrez: 29 10 2020
pubmed: 30 10 2020
medline: 11 11 2020
Statut: epublish

Résumé

Critical to facilitating SARS-CoV-2 point-of-care (POC) testing is assurance that viruses present in specimens are inactivated onsite prior to processing. Here, we conducted experiments to determine the virucidal activity of commercially available Viral Transport Mediums (VTMs) to inactivate SARS-CoV-2. Independent testing methods for viral inactivation testing were applied, including a previously described World Health Organization (WHO) protocol, in addition to a buffer exchange method where the virus is physically separated from the VTM post exposure. The latter method enables sensitive detection of viral viability at higher viral titre when incubated with VTM. We demonstrate that VTM formulations, Primestore

Identifiants

pubmed: 33114233
pii: v12111208
doi: 10.3390/v12111208
pmc: PMC7690900
pii:
doi:

Substances chimiques

Culture Media 0

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI098775
Pays : United States

Références

Clin Chem. 2020 Jun 1;66(6):794-801
pubmed: 32246822
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
J Clin Microbiol. 2012 Mar;50(3):1064-5
pubmed: 22205810
PLoS One. 2021 Sep 15;16(9):e0256813
pubmed: 34525109
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29142048
Emerg Infect Dis. 2020 Jul;26(7):1592-1595
pubmed: 32284092
Epidemiol Infect. 2011 Nov;139(11):1764-73
pubmed: 21205332
J Gen Virol. 2021 Mar;102(3):
pubmed: 33416462
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32303565
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24450-24458
pubmed: 32900935
Diagn Microbiol Infect Dis. 2003 Mar;45(3):191-7
pubmed: 12663160
Lancet Respir Med. 2020 Sep;8(9):e70
pubmed: 32771081
J Clin Microbiol. 2016 Dec;54(12):3050-3055
pubmed: 27733636
Viruses. 2020 Jun 08;12(6):
pubmed: 32521706
J Clin Med. 2019 Dec 04;8(12):
pubmed: 31817201
J Virol Methods. 2017 Dec;250:34-40
pubmed: 28941617
Am J Infect Control. 2020 Aug;48(8):972-973
pubmed: 32461067
Int J Tuberc Lung Dis. 2016 Aug;20(8):1118-24
pubmed: 27393549

Auteurs

David van Bockel (D)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

C Mee Ling Munier (CML)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Stuart Turville (S)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Steven G Badman (SG)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Gregory Walker (G)

NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2052, Australia.

Alberto Ospina Stella (AO)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Anupriya Aggarwal (A)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Malinna Yeang (M)

NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2052, Australia.

Anna Condylios (A)

NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2052, Australia.

Anthony D Kelleher (AD)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Tanya L Applegate (TL)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Andrew Vallely (A)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

David Whiley (D)

NSW State Reference Laboratory for HIV-AIDS/St Vincent's Hospital Sydney, St Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney Limited, Darlinghurst, NSW 2010, Australia.
Australia Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, QLD 4006, Australia.

William Rawlinson (W)

NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW 2052, Australia.

Phillip Cunningham (P)

Centre for Clinical Research, The University of Queensland, Royal Brisbane and Women's Hospital Campus, Herston, QLD 4006, Australia.

John Kaldor (J)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Rebecca Guy (R)

Kirby Institute for Infection and Immunity in Society, UNSW Medicine, UNSW Sydney, Kensington, NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH